Aileron Therapeutics Files 8-K with Board and Compensation Updates
Ticker: RNTX · Form: 8-K · Filed: Mar 15, 2024 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Aileron Therapeutics Inc (RNTX) |
| Form Type | 8-K |
| Filed Date | Mar 15, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, filing
Related Tickers: ALRN
TL;DR
Aileron Therapeutics (ALRN) filed an 8-K detailing board changes and executive comp. Watch for governance shifts.
AI Summary
Aileron Therapeutics, Inc. announced on March 11, 2024, changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, indicating ongoing operational and financial reporting.
Why It Matters
This 8-K filing provides crucial updates on Aileron Therapeutics' corporate governance and executive compensation, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can signal shifts in company strategy or internal dynamics, warranting closer investor scrutiny.
Key Players & Entities
- Aileron Therapeutics, Inc. (company) — Registrant
- March 11, 2024 (date) — Date of earliest event reported
- 001-38130 (other) — SEC File Number
- 13-4196017 (other) — IRS Employer Identification No.
- 738 Main Street #398 Waltham, MA 02451 (address) — Principal Executive Offices
- (617) 995-0900 (phone_number) — Registrant's telephone number
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Election of Directors', but the specific details of these changes are not elaborated in the provided text.
What are the key updates regarding executive compensation?
The filing mentions 'Compensatory Arrangements of Certain Officers', suggesting updates or new arrangements, but the specifics are not detailed in the excerpt.
What is the primary purpose of this 8-K filing?
The primary purpose is to report current information regarding the departure/election of directors, appointment of officers, and executive compensation arrangements, as well as Regulation FD disclosures and financial statements/exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on March 11, 2024.
Where is Aileron Therapeutics, Inc. headquartered?
Aileron Therapeutics, Inc. is headquartered at 738 Main Street #398, Waltham, MA 02451.
Filing Stats: 1,196 words · 5 min read · ~4 pages · Grade level 10.2 · Accepted 2024-03-15 07:00:31
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
Filing Documents
- d787456d8k.htm (8-K) — 31KB
- d787456dex991.htm (EX-99.1) — 11KB
- g787456g0314222626238.jpg (GRAPHIC) — 3KB
- 0001193125-24-068566.txt ( ) — 169KB
- alrn-20240311.xsd (EX-101.SCH) — 3KB
- alrn-20240311_lab.xml (EX-101.LAB) — 17KB
- alrn-20240311_pre.xml (EX-101.PRE) — 11KB
- d787456d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by the Company on March 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AILERON THERAPEUTICS, INC. Date: March 15, 2024 By: /s/ Brian Windsor, Ph.D. Brian Windsor, Ph.D. President and Chief Executive Officer